Photodynamic Therapy for Cutaneous and Subcutaneous Malignant Neoplasms

McCaughan, James S.; Guy, Jerry T.; Hicks, William; Laufman, Leslie R.; Nims, Thomas A.; Walker, John

doi:10.1001/archsurg.1989.01410020081013

Cited by 82 publications

(25 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During the last 2 decades, photochemotherapy [(PCT); or photodynamic therapy (PDT)] has been developed into a useful clinical treatment for several types of tumors (Schuitmaker et al, 1996;Dougherty, 1981;Dougherty and Marcus, 1992;Moan and Berg, 1992;McCaughan et al, 1989). PCT involves the use of a tumor-localizing photosensitizer followed by the exposure of the tumor area to light.…”

mentioning

confidence: 99%

Protoporphyrin IX accumulation in cells treated with 5-aminolevulinic acid: Dependence on cell density, cell size and cell cycle

et al. 1998

View full text Add to dashboard Cite

mentioning

confidence: 99%

Protoporphyrin IX accumulation in cells treated with 5-aminolevulinic acid: Dependence on cell density, cell size and cell cycle

et al. 1998

View full text Add to dashboard Cite

“…Over the past 10 years, PDT with systemic Photofrin® has been used for multiple types of cutaneous and subcutaneous malignancies including basal cell carcinoma [7,45], widespread Bowen's disease [45--47], squamous cell carcinoma [48][49][50][51][52], metastatic and recurrent breast carcinoma [50,51,[53][54][55] and Kaposi's sarcoma [56]. In a few instances PDT has also been used for palliation of metastatic melanoma [ 50,51,54 ].…”

Section: Introduction and Early Clinical Resultsmentioning

confidence: 99%

“…In a few instances PDT has also been used for palliation of metastatic melanoma [ 50,51,54 ]. There is also experience with PDT on patients with non-malignant lesions such as psoriasis [ 57,58 ] as an alternative to psoralen UVA and encouraging results have been reported on the treatment of laryngeal warts [59].…”

Section: Introduction and Early Clinical Resultsmentioning

confidence: 99%

Photodynamic therapy: a promising new modality for the treatment of cancer

Schuitmaker

Baas

Leengoed

et al. 1996

Journal of Photochemistry and Photobiology B: Biology

273

128

View full text Add to dashboard Cite

The first reports on photodynamic therapy (PDT) date back to the 1970s. Since then, several thousands of patients, both with early stage and advanced stage solid tumours, have been treated with PDT and many claims have been made regarding its efficacy. Nevertheless, the therapy has not yet found general acceptance by oncologists. Therefore it seems legitimate to ask whether PDT can still be described as "'a promising new therapy in the treatment of cancer".Clinically, PDT has been mainly used for bladder cancer, lung cancer and in malignant diseases of the skin and upper aerodigestive tract. The sensitizer used in the photodynamic treatment of most patients is Photofrin®, (Photofrin®, the commercial name of dihematoporphyrin ether/ester, containing > 80% of the active porphyrin dimers/oligomers (A.M.R. Fisher, A.L. Murphee and C.J. Gomer, Clinical and preclinical photodynamictherapy, Review Series Article, Lasers Surg. Med., 17 (1995) 2-31 ). It is a complex mixture of porphyrins derived from hematoporphyrin. Although this sensitizer is effective, it is not the most suitable photosensitizer for PDT. Prolonged skin photosensitivity and the relatively low absorbance at 630 rim, a wavelength where tissue penetration of light is not optimal, have been frequently cited as negative aspects hindering general acceptance. A multitude of new sensitizers is currently under evaluation. Most of these "second generation photosensitizers" are chemically pure, absorb light at around 650 nm or greater and induce no or less general skin photosensitivity. Another novel approach is the photosensitization of neoplasms by the induction of endogenous photosensitizers through the application of 5-aminolevulinic acid (ALA). This article addresses the use of PDT in the disciplines mentioned above and attempts to indicate developments of PDT which could be necessary for this therapy to gain a wider acceptance in the various fields.

show abstract

“…(fig. 3) With systemic photosensitizers 40-100% remission of SCCs could be obtained [38,39,41,42]. In topical ALA-PDT, the CR rate was 60-92% for superficial SCCs [10,14,15,50] and 0-67% for nodular SCCs [10,15,50].…”

Section: Bowen's Diseasementioning

confidence: 99%

“…Even repeated PDT treatment yielded a CR rate of only 50-70% [10,13]. Incomplete response of BD may be due to the thickened epithelial layer with reduced ALA penetration [10,11,13,15,36,37,39,40,47,48,[51][52][53].…”

Section: Bowen's Diseasementioning

confidence: 99%

Photodynamic Diagnosis and Therapy in Dermatology

Fritsch

Lang

Neuse

et al. 1998

Skin Pharmacol Physiol

View full text Add to dashboard Cite

The topical application of δ-aminolevulinic acid (ALA) induces porphyrin formation in the skin, preferentially in tumor tissues. Irradiation of the porphyrin-enriched tumor tissue with Wood’s light leads to emission of a brick-red fluorescence. This principle may be used as a diagnostic procedure which may be termed photodynamic diagnosis (PDD). In ALA-PDD, tumors and precancerous lesions of the skin reveal a homogeneous, intensive red fluorescence. Psoriatic lesions also show a strong but inhomogeneous porphyrin fluorescence. ALA-induced porphyrin fluorescence in preoperative planning is a valuable method to determine the peripheral borders of a given tumor. The histopathological extensions of the tumors correlate well with the borders detected by the tumor-specific fluorescence. The main indications of PDD are the delineation of clinically ill-defined skin tumors and the control of the efficacy of other tumor therapies. Photodynamic therapy (PDT) utilizes exogenously applied or endogenously formed photosensitizers and their activation by light to induce cell death via formation of singlet oxygen and other free radicals. PDT is highly efficient in the treatment of solar keratoses and superficial basal cell carcinomas. Initial squamous cell carcinomas also show good response to ALA-PDT. During the last decade, numerous studies on PDT for dermatologic diseases were published, the more important ones are reviewed here.

show abstract

Photodynamic Therapy for Cutaneous and Subcutaneous Malignant Neoplasms

Cited by 82 publications

References 9 publications

Protoporphyrin IX accumulation in cells treated with 5-aminolevulinic acid: Dependence on cell density, cell size and cell cycle

Protoporphyrin IX accumulation in cells treated with 5-aminolevulinic acid: Dependence on cell density, cell size and cell cycle

Photodynamic therapy: a promising new modality for the treatment of cancer

Photodynamic Diagnosis and Therapy in Dermatology

Contact Info

Product

Resources

About